Search
Hisun Pharmaceutical Receives IND Approval for Innovative Drug HSK47977 Tablets
2025-06-09 /
Read about 0 minute
Author：小编
Hisun Pharmaceutical has recently announced that its independently developed global novel oral small molecule anti-tumor drug, HSK47977 tablets, has been granted Investigational New Drug (IND) application acceptance by the National Medical Products Administration. This groundbreaking medication is specifically designed for the treatment of lymphoma. Currently, no other drug targeting the same mechanism has entered clinical trials globally, and China lacks relevant clinical data on this front. Preclinical studies have demonstrated that HSK47977 exhibits promising anti-tumor efficacy both in vitro and in vivo, potentially offering a novel therapeutic option for lymphoma patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
